5. Medicines for diseases of the nervous system
5.1. Antiseizure medicines

**Indication**
Status epilepticus  
**ICD11 code:** 8A66

**INN**
Midazolam

**Medicine type**
Chemical agent

**List type**
Core (EML)  
(EMLc)

**Additional notes**
Midazolam injection may be used for buccal administration when solution for oromucosal administration is not available.

**Formulations**
- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**
Midazolam

**DrugBank**
Midazolam

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended amendments to the listing for midazolam for status epilepticus on the EML and EMLc to better describe the available dosage forms.